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Abstract
Aims: To determine whether a serine protease inhibitor treatment can prevent or minimize emphysema in mice.
Methods: C57BL/6 mice were subjected to porcine pancreatic elastase (PPE) nasal instillation to induce emphysema and
were treated with a serine protease inhibitor (rBmTI-A) before (Protocol 1) and after (Protocol 2) emphysema development.
In both protocols, we evaluated lung function to evaluate the airway resistance (Raw), tissue damping (Gtis) and tissue
elastance (Htis). The inflammatory profile was analyzed in the bronchoalveolar lavage (BALF) and through the use of
morphometry; we measured the mean linear intercept (Lm) (to verify alveolar enlargement), the volume proportion of
collagen and elastic fibers, and the numbers of macrophages and metalloprotease 12 (MMP-12) positive cells in the
parenchyma. We showed that at both time points, even after the emphysema was established, the rBmTI-A treatment was
sufficient to reverse the loss of elastic recoil measured by Htis, the alveolar enlargement and the increase in the total
number of cells in the BALF, with a primary decrease in the number of macrophages. Although, the treatment did not
control the increase in macrophages in the lung parenchyma, it was sufficient to decrease the number of positive cells for
MMP-12 and reduce the volume of collagen fibers, which was increased in PPE groups. These findings attest to the
importance of MMP-12 in PPE-induced emphysema and suggest that this metalloprotease could be an effective therapeutic
target.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is character-
ized by a chronic airflow limitation caused by small airway disease
(obstructive bronchiolitis) and parenchymal destruction (emphy-
sema). It is the fourth leading cause of death throughout the world,
and further increases in the disease prevalence are predicted in the
coming decades [1].
In emphysema there is an abnormal enlargement of the distal
alveoli accompanied by the destruction of their walls without
obvious fibrosis [1], and an imbalance between the proteases and
anti-proteases still remains the principal hypothesis to explain the
pathogenesis of this disease [2].
Although there are many clinical and experimental studies on
the physiopathological mechanisms in emphysema, there are no
effective pharmacotherapeutic strategies to inhibit the progression
of alveolar wall destruction.
Emphysema in cigarette smokers is believed to be mediated by
elastolytic proteases released by inflammatory cells that locally
overwhelm or evade inhibitors, causing destruction of the elastin
and other extracellular matrix proteins in the alveolar walls [3,4].
There is no consensus on which specific cell(s) and which
proteases are the most important to emphysema development.
Both serine proteases and matrix metalloproteases are expressed in
human emphysema, and animal models involving the instillation
of neutrophil elastase [5] and knockout mice for metalloprotease
12 (MMP-12) [4] have been used to clarify the pathogenesis of this
disease.
Some studies have shown that protease inhibitors have positive
effects against emphysema progression in animal models [6,7,8].
Wright et al. [9] showed that guinea pigs exposed to cigarette-
smoke either acutely or chronically and treated with a serine
elastase inhibitor (ZD0892) showed a reduction in inflammatory
activity and in parenchymal destruction. Kuraki et al. [10]
demonstrated that prior treatment with an oral neutrophil elastase
inhibitor (ONO-6818) could inhibit lung hemorrhage and the
accumulation of neutrophils in the lung of rats at the acute phase
of lung injury induced by human neutrophil elastase; in long term
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studies, the administration of the same inhibitor at 8 weeks after
HNE (Human Neutrophil Elastase) prevented HNE-induced
emphysema.
In the current study, we verified the effects of treatment with the
Kunitz-type serine protease inhibitor from the cattle tick
Rhipicephalus (B.) microplus (rBmTI-A) in an elastase-induced
model in mice both before and after emphysema development.
The Kunitz type serine protease inhibitor is a canonical
inhibitor of serine proteases which domain has molecular mass
around 7000 Da with three disulfide bridges, characterizing a
protein with a stabilized structure [11]. Rhipicephalus (B.) microplus is
a very important bovine ectoparasite with an extensive geographic
distribution in tropical and subtropical regions of the world,
especially in Brazil [12]. In both the larvae and eggs of these ticks,
a serine proteinase-inhibiting activity has been described that
protects the host from infection by pathogens or parasites, inhibits
fungal or bacterial proteinases, and which likely regulates
proteinases involved in coagulation or cytokine activation [13].
Therefore, we postulated that treatment with a recombinant
serine protease inhibitor (rBmTI-A) in the animals that received
porcine pancreatic elastase (PPE) by nasal instillation could
prevent or minimize emphysema development.
Methods
This study was approved by the Review Board for human and
animal studies of the School of Medicine of University of Sa˜o
Paulo (Sa˜o Paulo, Brazil). Six- to eight-week old male C57BL/6
mice were used in this study. All the animals in the study received
humane care in compliance with the Guide for the Care and Use
of Laboratory Animals (NIH publication 85-23, revised 1985).
Induction of emphysema
To induce emphysema, the animals received a nasal instillation
of 50 mL (0.667 IU) of porcine pancreatic elastase (PPE)
(6.6 units/mg, E-1250, Type I) (Sigma, St. Louis, MO) [14].
The control groups received 50 mL of 0.9% NaCl (saline solution),
the PPE vehicle.
Preparation of the rBmTI-A
BmTI-A cDNA determination. Engorged female Rhipiceph-
alus Boophilus microplus ticks were provided by Dr. Itabajara da Silva
Vaz Junior of Universidade Federal do Rio Grande do Sul, Brazil.
Pichia pastoris (GS115) and the vector pPIC9K were purchased
from Invitrogen (San Diego, CA).
The cDNA sequence encoding the native BmTI-A inhibitor,
GenBank accession number P83609, isolated from a larval extract
[15], was identified in the DFCI Gene Indices Information Page
(accession number: TC20102). The sequence analyses were
performed using the BLAST algorithm [16]. The alignment of
the protein sequences was performed with the ClustalW program,
version 1.83 [17].
Construction of pPIC9K-BmTI-A. The BmTI-A gene was
amplified by PCR using B. microplus ovary cDNA as a template.
The SnaBI and NotI restriction sites were added to the sense
primer fBmTI-A (59 GAAGCTTACGTATCGCAACCA-
CATGTG AACCC39) and anti-sense primer rBmTI-A (59
AAAGAATGCGGCCGCTTATGA TTTCTTGCAGCTGTT-
TAGGC 39), respectively. The gene was digested with the SnaBI
and NotI restriction enzymes, and the fragment was ligated into
the plasmid pPIC9K (Invitrogen, San Diego, CA). The resulting
plasmid (pPIC9K-BmTI-A) was linearized with the SacI restric-
tion enzyme that was used in the transformation of the competent
P. pastoris GS115 yeast strain cells, prepared according to the
manufacturer’s instructions. rBmTI-A followed the methodology
of Sasaki and Tanaka, 2008 [18]. The transformed yeast were
incubated for 5 days in buffered methanol-complex medium
(BMMY). After cultivation, the yeast cells were harvested by
centrifugation (40006g, 20 min, 4uC) and the supernatant
containing the inhibitory activity was stored at 220uC.
The recombinant BmTI-A (rBmTI-A) purification. The
purification of rBmTI-A expressed in the P. pastoris system was
carried out using two chromatographic steps: affinity chromatog-
raphy in a trypsin–Sepharose column and reverse-phase chroma-
tography in a Sephasil Peptide C8 column (Amersham Biosciences,
Uppsala, Sweden). The culture supernatant containing the
rBmTI-A was applied to a trypsin–Sepharose column previously
equilibrated with 50 mM Tris–HCl buffer, pH 8.0 (buffer A). The
weakly bound proteins were washed out with buffer A containing
0.2 M NaCl, and the rBmTI-A was eluted with a 0.2 M KCl
solution at pH 2.0. The eluted fractions were immediately
neutralized using 1 M Tris–HCl buffer, pH 8.0. The fractions
containing the rBmTI-A were pooled, dialyzed, lyophilized,
suspended in buffer A and applied to a Sephasil Peptide C8
column.
To verify that the protease inhibitor treatment prevented or
minimized the elastase-induced emphysema in mice, the treatment
with rBmTI-A was performed using two different protocols with
different time points, namely, before the emphysema development
and 21 days after the PPE instillation, and in lungs with established
emphysema.
Experimental groups
In order to assess the therapeutic effects of rBmTI-A in mice
emphysema model, animals were divided into groups according to
the treatment protocols as follows:
Protocol 1: C57BL/6 mice (20–25 g) received either a nasal
instillation of 50 ml (0.667 UI) of porcine pancreatic elastase (PPE)
or normal saline (S), and 1 hour later the animals received a single
dose of the protease inhibitor (rBmTI-A, 35.54 pmol, by nasal
instillation) or vehicle (VE). The animals were divided in 4
experimental groups: S-VE (n= 7), S-rBmTIA (n = 10), PPE-VE
(n= 8) and PPE-rBMTIA (n= 10).
Protocol 2: C57BL/6 mice (20–25 g) received either a nasal
instillation of 50 ml (0.667 UI) of porcine pancreatic elastase (PPE)
or normal saline (S), and 21 days later the animals received two
doses of either a protease inhibitor (rBmTI-A, 35.54 pmol, by
nasal instillation) or vehicle (VE) with a 7-day interval. The
animals were divided in 4 experimental groups: S-VE (2 doses)
(n = 10), S-rBmTIA (2 doses) (n = 8), PPE-VE (2 doses) (n = 9) and
PPE-rBMTIA (2 doses) (n = 10).
Respiratory mechanics
The animals were deeply anesthetized by an intraperitoneal
injection of thiopental (70 mg/kg), tracheostomized and then
connected to a ventilator for small animals (FlexiVent, SCIREQ,
Scientific Respiratory Equipment, Montreal, Quebec). Also, they
were paralyzed with pancuronium bromide (1 mg/Kg), and the
anesthetic level was checked during the entire procedure.
Mice were mechanically ventilated with a tidal volume of
10 mL/kg and breathing frequency of 120 breaths/min. The
respiratory system input impedance (Zrs) was measured by
applying 3 s of oscillatory volume perturbation (frequencies from
0.25 to 9.125 Hz) to the tracheal cannula. To calculate the
respiratory mechanics parameters of airway resistance (Raw), tissue
damping (G) and tissue elastance (H) from Zrs data, we used the
constant phase model described by Hantos et al. [19]:
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The Raw parameter reflects the airway components, while Gtis
and Htis embody energy dissipation and storage, respectively,
within the tissues [20].
Bronchoalveolar Lavage Fluid (BALF)
At the end of the respiratory mechanics assessment, the animals
were exsanguinated via the abdominal aorta and the BALF was
collected. The trachea was cannulated and the BALF was
obtained by washing the airway lumen with 360.5 mL of sterile
saline. The recovery volume was over 95% of the instilled fluid
and was put into a test tube on ice. The white blood cells was
quantified by total and differential counting. The BALF was
centrifuged at 8006for 10 min and the cell pellet was resuspended
in 0.2 mL of sterile saline. The total number of viable cells was
determined in a Neubauer hemocytometer counting chamber.
The differential cell counts were performed in cytocentrifuge
preparations of the BALF (450 rpm for 6 min) (Cytospin,
Cheshire, UK) stained with Diff-Quick (Biochemical Sciences
Inc., Swedesboro, NJ). At least 300 cells were counted according to
standard morphologic criteria.
Lung Biopsies Preparation
At the end of the respiratory mechanics evaluation, the
abdominal wall was opened, and the animals were exsanguinated
via the abdominal aorta. The thoracic cavity was then opened,
and the lungs were removed. Both the lungs were fixed using 10%
buffered formalin infused through the trachea at a constant
pressure of 20 cm H20 for 24 hours and then embedded in
paraffin. Lung tissue sections (5 mm) were stained with H&E for
lung structure analysis, using Sirius Red (for collagen fibers) and
Resorcin-Fuchsin (for elastic fibers).
Immunohistochemistry
The tissue sections were deparaffinized and hydrated. After
blocking the endogenous peroxidase activity, an antigen retrieval
step was performed with either high-temperature citrate buffer
(pH=6.0) or trypsin. The following primary antibodies were used
in this study: a goat polyclonal anti-mouse MMP-12 (1:60, Santa
Cruz Biotechnology, CA, USA) and an anti-mouse macrophage
marker MAC-2 (1:30,000, clone M3/38, Cedarlane, ON,
Canada). The Vectastain ABC Kit (Vector Laboratories, Burlin-
game, CA, USA) was used in conjunction with a species-specific
secondary antibody, and 3-diaminobenzidine (DAB, Sigma, St.
Louis, MO, USA) was used as the chromogen. The sections were
counterstained with Harris’s hematoxylin. As a negative control,
the primary antibody was omitted from the procedure, and BSA
was used instead.
Morphometry
For conventional morphometry, an eyepiece with a coherent
system of 50 lines, 100 points and a known area, which was
attached to the microscope reticle, was used. The mean linear
intercept (Lm), an indicator of the mean alveolar diameter [21],
was assessed in 20 non-overlapping fields of the lung parenchyma
per animal at 2006 magnification. The volume proportion of
collagen and elastic fibers in the alveolar parenchyma were
determined using the same eyepiece. We counted the number of
points hitting a specific fiber in the alveolar parenchyma and
compared that with the number of points hitting the alveolar tissue
in each field to generate each proportion at 4006magnification.
The number of macrophages and the number of MMP-12-
expressing cells in the alveolar parenchyma were also assessed by a
point-counting technique. Using the eyepiece (62,500 mm2 at
4006magnification), the number of points in each field contacting
the alveolar tissue was counted. The alveolar tissue area in each
field was calculated as the number of points intersecting the
alveolar tissue as a proportion of the total grid area.
Statistical analysis
All of the data are expressed as the means and SD. A statistical
analysis was performed using SigmaStat software (SPSS Inc.
Chicago, Illinois, USA). The values were compared using a two-
way ANOVA followed by all pairwise multiple comparison
procedures (Holm-Sidak method). A p-value of less than 0.05
was considered to be significant.
Results
Respiratory mechanics
Figure 1 shows the mean values and SD of the respiratory
mechanics parameters. In the first protocol, there was a significant
decrease in the Htis only in the PPE-VE group (p= 0.032), while
the Gtis analysis showed significant differences between the PPE
and S groups that were independent of the rBmTI-A treatment
(p = 0.004). In the second protocol, there was a significant decrease
in the Htis (p = 0.009) and Gtis (p = 0.011) values in both groups
that received the PPE instillation compared with the S groups. We
did not observe differences in the Raw values between the
experimental groups.
Bronchoalveolar Lavage Fluid (BALF)
In the first protocol, the bronchoalveolar lavage fluid analysis
showed an increase in the total number of cells in both groups that
received the PPE (p = 0.02). The numbers of macrophages
(*p = 0.02) and lymphocytes (*p = 0.03) were increased in the
PPE groups, and the treatment with rBmTI-A decreased only the
number of macrophages (**p= 0.04) (Figure 2A). Additionally, in
the second protocol, there was an increase in the total number of
cells in the PPE groups (*p#0.01), however there was a decrease in
the PPE-rBmTIA compared with the PPE-VE group (**p p#
0.01). The differential count of the cells showed an increase in
macrophages (*p = 0.005) and lymphocytes (*p#0.01) in the PPE
groups, and rBmTI-A treatment decreased the number of
macrophages (**p= 0.013).
Mean Linear Intercept (Lm)
In the first (Figure 3A) and second protocols (Figure 3B), there
was an increase in the Lm mean values and SD in the PPE groups
compared with the S groups (*p = 0.037, 3A; and *p#0.03, 3B),
however the PPE-rBmTIA groups showed lower values compared
with the PPE-VE groups (3A and 3B, **p#0.001).
Volume proportion of collagen and elastic fibers
In Figure 4, the mean values and SD of the volume proportions
of collagen fibers (A) and elastic fibers (B) are shown. There was an
increase in collagen fibers in the PPE-VE groups compared with
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Figure 1. Htis, Gtis and Raw parameters in the first and second protocols are represented in Figures 1 A and B, respectively. A)
* p = 0.032 compared to the other groups; ** p = 0.004 compared to S-VE and S- rBmTIA groups. B) * p= 0.009 compared to S-VE and S-rBmTIA
groups; ** p= 0.011 compared to S-VE and S-rBmTIA groups. There were no significant differences in Raw values among the experimental groups.
Values are means and SD.
doi:10.1371/journal.pone.0098216.g001
Figure 2. BALF analyses in the first and second protocols are shown in figures 2A and B, respectively. A) Total Cells: * p = 0.02 compared
to S groups; Macrophages: 1 p= 0.02 compared to S groups and 11 p= 0.004 compared to PPE-VE; Lymphocytes: # p= 0.03 compared to S groups. B)
Total Cells: * p#0.01 compared to S groups and ** p#0.01 compared to PPE-VE group; Macrophages: 1 p=0.05 compared to S Groups and
11 p= 0.013 compared to PPE-VE group; Lymphocytes: #p#0.01 compared to the other groups. Values are means and SD.
doi:10.1371/journal.pone.0098216.g002
Figure 3. Mean linear intercept (Lm) values measured in the first (A) and second (B) protocols (means and SD). A) * p,0.001 compared
to S-VE and S-rBmTIA groups; ** p,0.001 compared to PPE-VE group. B) * p,0.001 compared to S-VE and S- rBmTIA groups; ** p = 0.04 compared to
PPE-VE group.
doi:10.1371/journal.pone.0098216.g003
Protease Inhibitor Treatment Ameliorates Emphysema
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e98216
the others (*p,0.05), while the elastic fibers were increased in the
PPE-VE and PPE-rBmTIA compared with the S groups (*p,
0.05) in both protocols.
Lung immunohistochemistry
Although in the first protocol, the number of cells positive for
MAC-2 was increased in the alveolar tissue of the mice that
received the PPE nasal instillation (*p = 0.037), only the PPE-VE
group showed higher values for MMP-12 (*p = 0.024) (Figure 5A).
After the development of emphysema (Figure 5B), both groups
that received the PPE instillation showed an increase in the
number of MAC-2-positive (*p = 0.01) and MMP-12-positive
(*p = 0.003) cells. However, the PPE-rBmTIA showed lower
values compared with PPE-VE (*p,0.001).
Discussion
In this study we evaluated the effects of a recombinant protease
inhibitor treatment (rBmTI-A) before and after the development of
emphysema in mice. The original protease inhibitor BmTI-A was
not used, since its production requires a large amount of larvae
ticks that are difficult to obtain in order to produce an enough
amount of native inhibitor. Thus, we decided to use the strategy of
cloning, expressing and purifying the recombinant inhibitor
rBmTI-A. In addition, the recombinant inhibitor rBmTI-A
presents the same inhibitory activities toward bovine trypsin,
human neutrophil elastase (HNE), Human plasma Kallikrein
(HuPK) and plasmin, all the Ki in nano molar rate. The
recombinant inhibitor is a better inhibitor to HuPK and plasmin
than the native inhibitor BmTI-A [15].
Figure 4. Volume proportion of collagen and elastic fibers are shown in the first (A) and second protocols (B). A) * p= 0.031 compared
to the other groups; ** p#0.001 compared to S groups; B) * p = 0.035 compared to the other groups; ** p = 0.0003 compared to S groups. Values are
means and SD.
doi:10.1371/journal.pone.0098216.g004
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We found an effective decrease in alveolar enlargement at both
time points, including 21 days after the PPE instillation, when the
emphysema was already established. Since Lm is a measurement
of the average space between opposing alveolar walls [21] and the
emphysema is characterized by alveolar wall destruction [1], the
Lm increase in PPE groups in both protocols suggests emphysema
development in this experimental model and that the rBmTI-A
treatment decreased these parenchymal lesions.
Additionally, the inflammatory profile analysis in the BALF
showed a decrease in the total number of cells after the protease
inhibitor treatment, with a decrease in the number of macro-
phages at the different time points.
In COPD patients, macrophages are predominant in the
bronchoalveolar lavage and are believed to play an important
role in the underlying inflammation in the distal airways
[22,23,24]. It was demonstrated in resected human lungs that
the extent of emphysema was directly related to an increase in the
number of macrophages but not of neutrophils [25].
Although the morphometric analysis of the lung parenchyma
showed that the treatment with rBmTI-A did not control the
increase in macrophages either before or after the development of
emphysema, we observed that the treatment with this inhibitor
was sufficient to prevent an increase in the number of MMP-12
positive cells when it was administered 1 h after the emphysema
induction by PPE nasal instillation. Even though the rBmTI-A
treatment administered after emphysema development resulted in
a decrease in MMP-12 positive cells in the PPE-rBMTIA
compared with the PPE-VE groups, the PPE-rBMTIA group
continued to have higher values compared with the control
groups.
Since Hautamaki et al. [26] reported that knockout mice for
MMP-12 did not develop emphysema after exposure to cigarette
smoke, MMP-12 has been described as a metalloprotease released
Figure 5. Positive cells for MAC-2 and MMP-12 in the first and second protocols (Figure 5A and B, respectively). A) * p = 0.037
compared to S-VE and S- rBmTIA groups; ** p = 0.024 compared to the other groups. B) * p= 0.011 compared to S-VE and S- rBmTIA groups;
** p = 0.003 compared to S-VE and S- rBmTIA groups; # p#0.01 compared to PPE-VE group. Values are means and SD.
doi:10.1371/journal.pone.0098216.g005
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mainly by macrophages, and it is suggested as an important
elastolytic enzyme responsible for emphysematous lesions in
rodents. In our study, the rBmTI-A treatment was sufficient to
reduce the number of cells positive for MMP-12, which could
explain the inhibitory effects of rBmTI-A on the parenchymal
destruction.
In emphysema, the progressive chronic inflammatory response
in the lung tissues is associated with a dynamic tissue repair and
remodeling process, which involves a structural reorganization of
the extracellular matrix (ECM) components [27], such as collagen
and elastic fibers. This could alter the lung viscoelastic properties,
as evaluated by respiratory mechanics analysis, such as the tissue
damping (Gtis) and tissue elastance (Htis) [28,29,30].
The respiratory mechanics analysis showed that the rBmTI-A
treatment was sufficient to reverse the loss of elastic recoil
measured by Htis in the PPE animals that received the protease
inhibitor treatment at both time points, suggesting that the rBmTI-
A instillation prevented and minimized the impairment of lung
function in these animals.
Our analysis of the elastic and collagen fibers revealed an
increase in the total numbers of both types of fibers in the PPE
compared with the control groups, and the rBmTI-A instillation
treatment was effective in reducing only the increase in collagen
fibers in the PPE groups at both time points; rBmTI-A did not
reduce the observed increase in the elastic fibers.
It is interesting that despite the increase in the number of elastic
fibers, we observed an improvement in lung function in the
animals that received the PPE instillation and rBmTI-A treatment.
Many studies have shown that in parenchymal lung injury, as in
our experimental model, the repair of elastic fibers is most likely
defective, resulting in non-functional fibers.
Elastic fibers are considered to be the major components
responsible for the elastic recoil properties of the lungs [31,32],
and they are composed of elastin and microfibrils (fibrillins,
microfibril-associated glycoproteins, and TGF-b binding proteins)
[31]. Fibrillin fibers assist in the formation of elastin polymers by
providing a scaffold that directs elastin aggregation. The mice
lacking elastin or elastic fiber proteins, such as fibrillin-1, show an
emphysema-like lung at birth [33,34,35]. In a previous study we
showed an increase in elastin in the PPE-exposed animals 28 days
after the emphysema induction with no increase in type I fibrillin
[36].
To better correlate our respiratory mechanics assessment results
with the fiber amount analysis, further investigations will be
necessary to evaluate which fiber types are present in greater
numbers in the animals with emphysema after the treatment with
the rBmTI-A and how these increased elastic fibers are arranged
into fibrillin and elastin subcomponents.
The rBmTI-A has been described as an inhibitor of neutrophil
elastase, trypsin and kallikrein. Until now, there has been no
description in the literature of the inhibitory effects of rBmTI-A on
MMP-12, or on any MMPs for that matter.
MMPs are generally released as latent precursors and the
proteolytic cleavage of the latent forms results in active proteases
[37]. Zhu et al. [37] demonstrated in a three-dimensional (3D)
collagen gel culture that monocytes and fibroblasts can release
MMP-1, -2, -3 and -9 and can degrade extracellular matrix in the
presence of neutrophil elastase. It is possible that, in our study,
these positive effects after the rBmTI-A treatment to minimize and
prevent emphysema in a PPE-induced model could be due to an
inhibition in neutrophil elastase and a consequent lack of MMP-12
activation.
These findings attest to the importance of MMP-12 in PPE-
induced emphysema and suggest that this metalloprotease could
be an effective target for therapy.
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